Mesoblast (MESO): which funds own it
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Sections with a free account
No concentrated manager holds it.
Who owns Mesoblast?
Mesoblast trades in the U.S. through ADRs, certificates that represent shares of a non-U.S. company. Form 13F counts ADRs while the company reports ordinary shares, so we do not compute percentages. Holders reporting more than 5% of the ordinary shares to the SEC (Schedules 13D/13G): Gueck William J., 5.0% (13G filed Sep 16, 2025). George Gregory is listed on Form 4 filings as an owner of more than 10%. As of Jun 30, 2026, the largest ADR holders reported on Form 13F were Morgan Stanley (718,608 ADRs), BlackRock (664,280 ADRs) and Susquehanna International Group, LLP (457,744 ADRs).
Which institutions hold the most Mesoblast shares?
Per Form 13F filings as of Jun 30, 2026, in ADRs:
- 1. Morgan Stanley: 718,608 ADRs
- 2. BlackRock: 664,280 ADRs
- 3. Susquehanna International Group, LLP: 457,744 ADRs
- 4. Goldman Sachs Group: 395,612 ADRs
- 5. BNP PARIBAS ASSET MANAGEMENT Holding: 259,700 ADRs
- 6. UBS Group: 200,053 ADRs
- 7. Arax Advisory Partners: 168,022 ADRs
- 8. Bank of America: 100,000 ADRs
- 9. Penbrook Management: 87,075 ADRs
- 10. M&g: 59,100 ADRs
Sources:13G by Gueck William J. (Sep 16, 2025) ↗All of the company's proxy statements on EDGAR ↗
We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.
Mesoblast revenue
Mesoblast reported annual revenue of $17.2 million for fiscal year 2025 (year ended June 30, 2025), according to its Form 20-F filed with the SEC (XBRL data).
Quarter flow (concentrated managers)
Concentrated managers holding it
None in the latest quarter.
Largest holders of MESO (all 13F filers)
- Morgan Stanley719 KBank or trading desk+204 K
- BlackRock664 KIndex manager+33 K
- Susquehanna International Group, LLP458 KBank or trading desk+71 K
- Goldman Sachs Group396 KBank or trading desk−1,603
- BNP PARIBAS ASSET MANAGEMENT Holding260 KInvestment firm+260 K
- UBS Group200 KBank or trading desk+67 K
- Arax Advisory Partners168 KType not verified+144 K
- Bank of America100 KBank or trading desk−4
- Penbrook Management87 KType not verified0
- M&g59 KType not verified0
- Shares
- 719 K
- Change
- +204 K
See more
- Type
- Bank or trading desk
- Value
- $9.7M
- Shares
- 664 K
- Change
- +33 K
See more
- Type
- Index manager
- Value
- $9.0M
- Shares
- 458 K
- Change
- +71 K
See more
- Type
- Bank or trading desk
- Value
- $6.2M
- Shares
- 396 K
- Change
- −1,603
See more
- Type
- Bank or trading desk
- Value
- $5.4M
- Shares
- 260 K
- Change
- +260 K
See more
- Type
- Investment firm
- Value
- $3.5M
- Shares
- 200 K
- Change
- +67 K
See more
- Type
- Bank or trading desk
- Value
- $2.7M
- Shares
- 168 K
- Change
- +144 K
See more
- Type
- Type not verified
- Value
- $2.3M
- Shares
- 100 K
- Change
- −4
See more
- Type
- Bank or trading desk
- Value
- $1.4M
- Penbrook Management
- Shares
- 87 K
- Change
- 0
See more
- Type
- Type not verified
- Value
- $1.2M
- Shares
- 59 K
- Change
- 0
See more
- Type
- Type not verified
- Value
- $827K
The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.
Insiders (Form 4)
10% owners who bought (6 m): 0
Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.
Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →
Above 5% (13D/13G)
Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.
This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.
- Gueck William J.5%13Gfiling ↗Event: Sep 12, 2025 · filed: Sep 16, 2025
Above 5% over time (13D/13G)
Each holder with its filings in order. History since December 2024.
This company filed no 8-K forms in the last year. Foreign companies listed in the US (ADRs) report material events on forms 6-K and 20-F, and ETFs and funds do not file 8-Ks. If it is a foreign company listed in the US through ADRs (American Depositary Receipts), what trades are bank-issued certificates that represent shares from its home market. See its filings on EDGAR ↗
Other Health Care stocks in managers' portfolios
Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.
- Agios PharmaceuticalsAGIO · 4 managers
- DavitaDVA · 4 managers
- KardiganKARD · 4 managers
- MapLight TherapeuticsMPLT · 4 managers
- Anteris Technologies GlobalAVR · 5 managers
- Compass TherapeuticsCMPX · 5 managers